Published in Hematology Am Soc Hematol Educ Program on December 05, 2015
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia (2016) 0.77
Effects of survivin on FVADT chemotherapy for refractory multiple myeloma. Exp Ther Med (2016) 0.75
Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy. Oncotarget (2016) 0.75
Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc (2015) 2.96
Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc (2014) 2.73
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc (2015) 0.88
Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc (2015) 0.86
Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood (2015) 0.83
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood (2015) 0.80
Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma. Blood (2017) 0.75
Efficacy of VDT PACE-like Regimens in Treatment of Relapsed/Refractory Multiple Myeloma. Am J Hematol (2017) 0.75
Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clin Proc (2016) 0.75
From the Guest Editor: Hematologic Cancers: A Decade of Progress in Targeted Therapy. Cancer J (2016) 0.75